PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17551476-7	2006	In GLUD1 and GCK mutations the disease is usually mild, has a late onset and is responsive to diazoxide.	Diazoxide	94-103	glucokinase	Homo sapiens	13-16	
20301549-9	1993	FHI-GCK, caused by pathogenic variants in GCK, may be much milder than FHI-KATP; however, some persons have severe, diazoxide-unresponsive hypoglycemia.	Diazoxide	116-125	glucokinase	Homo sapiens	42-45	
28270372-13	2017	Among the diazoxide-responsive cases, gene mutations were detected in 8 patients with ABCC8, 4 with KCNJ11, 5 with GLUD1, and 1 with GCK.	Diazoxide	10-19	glucokinase	Homo sapiens	133-136	
21186003-4	2011	Diazoxide is the first-line drug for the rare forms of CHI for long-term treatment but is not entirely effective in some of these rarer defects (GCK, MCT1).	Diazoxide	0-9	glucokinase	Homo sapiens	145-148	
17976205-2	2007	GCK-PHHI patients have regulated insulin secretion and can usually be treated with diazoxide.	Diazoxide	83-92	glucokinase	Homo sapiens	0-3